Pandemic (H1N1) 2009

European Vaccine Manufacturers statement on Council of Europe debate on the 'Faked pandemics - a threat for public health' (14th January 2010)

The research-based pharmaceutical industry is better prepared than ever to face a pandemic influenza threat and is committed to playing its part in protecting communities around the world against a pandemic influenza threat. It will continue to work closely with the Department of Health and Children and the WHO to address different aspects of this serious public health challenge.

Influenza Vaccines and Antivirals

When the Pandemic (H1N1) 2009 outbreak began, vaccine and pharmaceutical manufacturers began their own internal preparations to respond to the situation. Measures undertaken included preparing to produce a targeted Pandemic (H1N1) 2009 vaccine and increasing the manufacture of antivirals. In addition, the International Federation of Pharmaceutical Manufacturers and Associations, of which the IPHA is a member, has been in close contact with the WHO to facilitate timely technical preparations for vaccine production.

In addition, antiviral manufacturers have provided the WHO with stockpiles that have already been distributed to countries in need and are now replenishing those stockpiles. Looking at the broader implications of a pandemic, extensive plans have been made to ensure that companies can continue to produce and distribute essential medicines of all kinds during an influenza pandemic.

Business Continuity Measures

Pharmaceutical companies have also developed business continuity plans to ensure that they are able to maintain production and distribution of essential medicines during a possible influenza pandemic.

To assist member companies in their planning, IPHA developed detailed guidance outlining the key areas that pandemic influenza business continuity plans should address.

Pandemic Influenza Prepardness - Business Continuity Planning for the Pharmaceutical Industry in Ireland (1.11 MB, Adobe PDF)